

FACULTY OF: Pharmaceutical Sciences **DEPARTMENT OF**: Pharmaceutics

SEMESTER: VIII CODE: BP801T

NAME: Biostatistics and Research Methodology- Theory

Teaching & Evaluation Scheme: -

		Teaching Scheme (Hours)					Evaluation Scheme								
Subject	Name of the			Pr	Total	Credits		Th	eory		Practical				
Code	Subject	Th	Tu				Internal Exam		End Semester Exam		Internal Exam		End Semester Exam		Total
							Marks	Hrs	Marks	Hrs	Marks	Hrs	Marks	Hrs	
	Biostatistics and Research						15	1							
BP801T	Methodology- Theory	3	1		4	4	10 (CM)		75	3					100

Scope: To understand the applications of Biostatics in Pharmacy. This subject deals with descriptive statistics, Graphics, Correlation, Regression, logistic regression Probability theory, Sampling technique, Parametric tests, Non Parametric tests, ANOVA, Introduction to Design of Experiments, Phases of Clinical trials and Observational and Experimental studies, SPSS, R and MINITAB statistical software's, analyzing the statistical data using Excel.

Objectives: Upon completion of the course the student shall be able to:

- Know the operation of M.S. Excel, SPSS, R and MINITAB®, DoE (Design of Experiment)
- Know the various statistical techniques to solve statistical problems
- Appreciate statistical techniques in solving the problems.

UNIT	COURSE CONTENT (45 Hours)	HR.
I	 Introduction: Statistics, Biostatistics, Frequency distribution Measures of central tendency: Mean, Median, Mode- Pharmaceutical examples Measures of dispersion: Dispersion, Range, standard deviation, Pharmaceuticalproblems Correlation: Definition, Karl Pearson's coefficient of correlation, Multiple correlation -Pharmaceuticals examples 	10
II	 Regression: Curve fitting by the method of least squares, fitting the lines y= a + bx and x= a + by, Multiple regression, standard error of regression—	10



	distribution, Poisson's distribution, properties – problems Sample, Population,	
	large sample, small sample, Null hypothesis, alternative hypothesis, sampling,	
	essence of sampling, types of sampling, Error-I type, Error-II type, Standard	
	error of mean (SEM) - Pharmaceutical examples	
	• Parametric test: t-test(Sample, Pooled or Unpaired and Paired), ANOVA,	
	(One way and Two way), Least Significance difference	
	• Non Parametric tests: Wilcoxon Rank Sum Test, Mann-Whitney U test,	
	Kruskal-Wallistest, Friedman Test	
	• Introduction to Research: Need for research, Need for design of	
	Experiments, Experiential Design Technique, plagiarism	
***	• Graphs: Histogram, Pie Chart, Cubic Graph, response surface plot, Counter	10
III	Plot graph	10
	• Designing the methodology: Sample size determination and Power of a study,	
	Report writing and presentation of data, Protocol, Cohorts studies,	
	Observational studies, Experimental studies, Designing clinical trial, various	
	phases.	
	Blocking and confounding system for Two-level factorials	
	• Regression modeling: Hypothesis testing in Simple and Multiple regression	
	models	
IV	• Introduction to Practical components of Industrial and Clinical Trials	08
	Problems: Statistical Analysis Using Excel, SPSS, MINITAB®, DESIGN OF	
	EXPERIMENTS, R -Online Statistical Software's to Industrial and Clinical	
	trial approach	
	• Design and Analysis of experiments:	
\mathbf{V}	• Factorial Design: Definition, 2 ² , 2 ³ design. Advantage of factorial design	07
	• Response Surface methodology: Central composite design, Historical design,	
	Optimization Techniques	

Recommended Books (Latest edition):

- 1. Pharmaceutical statistics- Practical and clinical applications, Sanford Bolton, publisher Marcel Dekker Inc. New York.
- 2. Fundamental of Statistics Himalaya Publishing House- S.C. Guptha
- 3. Design and Analysis of Experiments –PHI Learning Private Limited, R Pannerselvam,
- 4. Design and Analysis of Experiments Wiley Students Edition, Douglas and C. Montgomery



FACULTY OF: Pharmaceutical Sciences **DEPARTMENT OF:** Pharmacology

SEMESTER: VIII CODE: BP802T

NAME: Social and Preventive Pharmacy - Theory

Teaching & Evaluation Scheme: -

	Name of the Subject	Teaching Scheme (Hours)					Evaluation Scheme								
Subject					Total	Credits		eory		Pra	ctical				
Code		Th	Tu	Pr			Internal		End Semester		Internal		End Semester		Total
							Exai	Exam		ì	Exam		Exam		Total
							Marks	Hrs	Marks	Hrs	Marks	Hrs	Marks	Hrs	
	Social and					4	15	1	75						
DD0000	Preventive	2	2 1		4					3					100
BP802T	Pharmacy-	3 1		4	4	10		13	3					100	
	Theory						(CM)								

Scope: The purpose of this course is to introduce to students a number of health issues and their challenges. This course also introduced a number of national health programs. The roles of the pharmacist in these contexts are also discussed.

Objectives: After the successful completion of this course, the student shall be able to:

- Acquire high consciousness/realization of current issues related to health and pharmaceutical
- Problems within the country and worldwide.
- Have a critical way of thinking based on current healthcare development.
- Evaluate alternative ways of solving problems related to health and Pharmaceutical issues

UNIT	COURSE CONTENT (45 Hours)	HR.
I	 Concept of health and disease: Definition, concepts and evaluation of public health. Understanding the concept of prevention and control of disease, social causes of diseases and social problems of the sick. Social and health education: Food in relation to nutrition and health, Balanced diet, Nutritional deficiencies, Vitamin deficiencies, Malnutrition and its prevention. Sociology and health: Socio cultural factors related to health and disease, Impact of urbanization on health and disease, Poverty and health Hygiene and health: personal hygiene and health care; avoidable habits 	10
II	• Preventive medicine: General principles of prevention and control of diseases	10



	such as cholera, SARS, Ebola virus, influenza, acute respiratory infections,	
	malaria, chickenguinea, dengue, lymphatic filariasis, pneumonia, hypertension,	
	diabetes mellitus, cancer, drug addiction-drug substance abuse	
	• National health programs, its objectives, functioning and outcome of the	
	following: HIV AND AIDS control programme, TB, Integrated disease	Ì
III	surveillance program (IDSP), National leprosy control programme, National	10
	mental health program, National programme for prevention and control of	10
	deafness, Universal immunization programme, National programme for	
	control of blindness, Pulse polio programme.	İ
	National health intervention programme for mother and child, National family	
IV	welfare programme, National tobacco control programme, National Malaria	08
1 1	Prevention Program, National programme for the health care for the elderly,	Vo
	Social health programme; role of WHO in Indian national program	Ì
	• Community services in rural, urban and school health: Functions of PHC,	
\mathbf{V}	Improvement in rural sanitation, national urban health mission, Health	07
	promotion and education in school.	

Recommended Books (Latest edition):

- 1. Short Textbook of Preventive and Social Medicine, Prabhakara GN, 2nd Edition, 2010, ISBN: 9789380704104, JAYPEE Publications
- 2. Textbook of Preventive and Social Medicine (Mahajan and Gupta), Edited by Roy Rabindra Nath, Saha Indranil, 4th Edition, 2013, ISBN: 9789350901878, JAYPEE Publications
- 3. Review of Preventive and Social Medicine (Including Biostatistics), Jain Vivek, 6thEdition, 2014, ISBN: 9789351522331, JAYPEE Publications
- 4. Essentials of Community Medicine—A Practical Approach, Hiremath Lalita D, Hiremath Dhananjaya A, 2nd Edition, 2012, ISBN: 9789350250440, JAYPEE Publications
- 5. Park Textbook of Preventive and Social Medicine, K Park, 21st Edition, 2011, ISBN-14:9788190128285, BANARSIDAS BHANOT PUBLISHERS.
- 6. Community Pharmacy Practice, Ramesh Adepu, BSP publishers, Hyderabad

Recommended Journals:

1. Research in Social and Administrative Pharmacy, Elsevier, Ireland



FACULTY OF: Pharmaceutical Sciences **DEPARTMENT OF:** Pharmaceutics

SEMESTER: VIII CODE: BP803ET

NAME: Pharma Marketing Management-Theory

Teaching & Evaluation Scheme: -

		Teaching Scheme (Hours)					Evaluation Scheme									
Subject	Name of the					Credits		Th	eory		Practical					
Code	Subject	Th Tu		Pr	Total		Intern Exai		End Semo Exam		Interr Exar		End Sem Exan		Total	
							Marks	Hrs	Marks	Hrs	Marks	Hrs	Marks	Hrs		
	Pharma Marketing						15	1								
BP803ET	Management - Theory	3	1		4	4 10 75 3 (CM)					100					

Scope: The pharmaceutical industry not only needs highly qualified researchers, chemists and, technical people, but also requires skilled managers who can take the industry forward by managing and taking the complex decisions which are imperative for the growth of the industry. The Knowledge and Know-how of marketing management groom the people for taking a challenging role in Sales and Product management.

Course Objective: The course aims to provide an understanding of marketing concepts and techniques and their applications in the pharmaceutical industry.

UNIT	COURSE CONTENT (45 Hours)	HR.
I	 Marketing: Definition, general concepts and scope of marketing; Distinction between marketing &selling Marketing environment; Industry and competitive analysis; Analyzing consumer buying behavior; industrial buying behavior. Pharmaceutical market: Quantitative and qualitative aspects; size and composition of the market; demographic descriptions and socio-psychological characteristics of the consumer; market segmentation& targeting. Consumer profile; Motivation and prescribing habits of the physician; patients' choice of physician and retail pharmacist. Analyzing the Market; Role of market research. 	10
II	• Product decision: Classification, product line and product mix decisions, product lifecycle, product portfolio analysis; product positioning; New product decisions; Product branding, packaging and labeling decisions, Product management in pharmaceutical industry.	10



Ш	• Promotion: Methods, determinants of promotional mix, promotional budget; An overview of personal selling, advertising, direct mail, journals, sampling, retailing, medical exhibition, public relations, online promotional techniques for OTC Products.	10
IV	 Pharmaceutical marketing channels: Designing channel, channel members, selecting the appropriate channel, conflict in channels, physical distribution management: Strategic importance, tasks in physical distribution management. Professional sales representative (PSR): Duties of PSR, purpose of detailing, selection and training, supervising, norms for customer calls, motivating, evaluating, compensation and future prospects of the PSR. 	08
v	 Pricing: Meaning, importance, objectives, and determinants of price; pricing methods and strategies, issues in price management in pharmaceutical industry. An overview of DPCO (Drug Price Control Order) and NPPA (National Pharmaceutical Pricing Authority). Emerging concepts in marketing: Vertical & Horizontal Marketing; Rural Marketing; Consumerism; Industrial Marketing; Global Marketing. 	07

Recommended Books: (Latest Editions)

- 1. Philip Kotler and Kevin Lane Keller: Marketing Management, Prentice Hall of India, New Delhi
- 2. Walker, Boyd and Larreche: Marketing Strategy- Planning and Implementation, Tata MC GrawHill, New Delhi.
- 3. Dhruv Grewal and Michael Levy: Marketing, Tata MC Graw Hill
- 4. Arun Kumar and N Menakshi: Marketing Management, Vikas Publishing, India
- 5. Rajan Saxena: Marketing Management; Tata MC Graw-Hill (India Edition)
- 6. Ramaswamy, U.S & Nanakamari, S: Marketing Managemnt: Global Perspective, IndianContext, Macmilan India, New Delhi.
- 7. Shanker, Ravi: Service Marketing, Excell Books, New Delhi
- 8. Subba Rao Changanti, Pharmaceutical Marketing in India (GIFT Excel series) Excel Publications.



FACULTY OF: Pharmaceutical Sciences

DEPARTMENT OF: Pharmaceutical Chemistry

SEMESTER: VIII CODE: BP804ET

NAME: Pharmaceutical Regulatory Science-Theory

Teaching & Evaluation Scheme: -

	Name of the Subject	Teaching Scheme (Hours)					Evaluation Scheme								
Subject					Total	Credits		Th	eory		Practical				
Code		Th	Tu	Pr			Internal Exam		End Semester Exam		Internal Exam		End Semester Exam		Total
							Marks	Hrs	Marks	Hrs	Marks	Hrs	Marks	Hrs	
	Pharmaceutical						15	1							
BP804ET	Regulatory Science- Theory	3	1		4	4	10 (CM)		75	3					100

Scope: This course is designed to impart the fundamental knowledge on the regulatory requirements for approval of new drugs, and drug products in regulated markets of India & other countries like US, EU, Japan, Australia, UK etc. It prepares the students to learn in detail on the regulatory requirements, documentation requirements, and registration procedures for marketing the drug products.

Objectives: Upon completion of the subject student shall be able to;

- Know about the process of drug discovery and development
- Know the regulatory authorities and agencies governing the manufacture and sale of pharmaceuticals
- Know the regulatory approval process and their registration in Indian and international markets

UNIT	COURSE CONTENT (45 Hours)	HR.
I	• New Drug Discovery and development Stages of drug discovery, Drug development process, pre-clinical studies, non-clinical activities, clinical studies, Innovator and generics, Concept of generics, Generic drug product development.	10
II	 Regulatory Approval Process Approval processes and timelines involved in Investigational New Drug (IND), New Drug Application (NDA), Abbreviated New Drug Application (ANDA). Changes to an approved NDA / ANDA. Regulatory authorities and agencies Overview of regulatory authorities of India, United States, European Union, Australia, Japan, Canada (Organization structure and types of applications) 	10



III	Registration of Indian drug product in overseas market Procedure for export of pharmaceutical products, Technical documentation, Drug Master Files (DMF), Common Technical Document (CTD), electronic Common Technical Document (eCTD), ASEAN Common Technical Document (ACTD) research.	10
IV	• Clinical trials Developing clinical trial protocols, Institutional Review Board / Independent Ethics committee - formation and working procedures, Informed consent process and procedures, GCP obligations of Investigators, sponsors & Monitors, Managing and Monitoring clinical trials, Pharmacovigilance – safety monitoring in clinical trials	08
V	• Regulatory Concepts Basic terminology, guidance, guidelines, regulations, Laws and Acts, Orange book, Federal Register, Code of Federal Regulatory, Purple book	07

Recommended books (Latest edition):

- 1. Drug Regulatory Affairs by Sachin Itkar, Dr. N.S. Vyawahare, Nirali Prakashan.
- 2. The Pharmaceutical Regulatory Process, Second Edition Edited by Ira R. Berry and Robert P. Martin, Drugs and the Pharmaceutical Sciences, Vol.185. Informa Health care Publishers.
- 3. New Drug Approval Process: Accelerating Global Registrations by Richard a Guarino, MD, 5th edition, Drugs and the Pharmaceutical Sciences, Vol.190.
- 4. Guidebook for drug regulatory submissions / Sandy Weinberg. By John Wiley & Sons. Inc.
- 5. FDA Regulatory Affairs: a guide for prescription drugs, medical devices, and biologics /edited by Douglas J. Pisano, David Mantus.
- 6. Generic Drug Product Development, Solid Oral Dosage forms, Leon Shargel and Isader Kaufer, Marcel Dekker series, Vol.143
- 7. Clinical Trials and Human Research: A Practical Guide to Regulatory Compliance by Fay A. Rozovsky and Rodney K. Adams
- 8. Principles and Practices of Clinical Research, Second Edition Edited by John I. Gallin and Frederick P. Ognibene
- 9. Drugs: From Discovery to Approval, Second Edition by Rick Ng



FACULTY OF: Pharmaceutical Sciences **DEPARTMENT OF:** Pharmacology

SEMESTER: VIII CODE: BP805ET

NAME: Pharmacovigilance -Theory

Teaching & Evaluation Scheme: -

	Name of the Subject	Teaching Scheme (Hours)					Evaluation Scheme									
Subject								Th	eory		Practical					
Code		Th	Tu	Pr	Total Cr	Credits		Internal End Exam		End Semester Exam		nal m	End Semester Exam		Total	
							Marks	Hrs	Marks	Hrs	Marks	Hrs	Marks	Hrs		
	Dhamaaayiailanaa						15	1								
BP805ET	Pharmacovigilance - Theory	3	1		4	4	10 (CM)		75	3					100	

Scope: This paper will provide an opportunity for the student to learn about development of pharmacovigilance as a science, basic terminologies used in pharmacovigilance, global scenario of Pharmacovigilance, train students on establishing pharmacovigilance programme in an organization, various methods that can be used to generate safety data and signal detection. This paper also develops the skills of classifying drugs, diseases and adverse drug reactions.

Objectives: At completion of this paper it is expected that students will be able to (know, do, and appreciate):

- Why drug safety monitoring is important?
- History and development of pharmacovigilance
- National and international scenario of pharmacovigilance
- Dictionaries, coding and terminologies used in pharmacovigilance
- Detection of new adverse drug reactions and their assessment
- International standards for classification of diseases and drugs
- Adverse drug reaction reporting systems and communication in pharmacovigilance
- Methods to generate safety data during pre-clinical, clinical and post approval phases of drugs' life cycle
- Drug safety evaluation in paediatrics, geriatrics, pregnancy and lactation
- Pharmacovigilance Program of India (PvPI) requirement for ADR reporting in India
- ICH guidelines for ICSR, PSUR, expedited reporting, pharmacovigilance planning
- CIOMS requirements for ADR reporting
- Writing case narratives of adverse events and their quality.



UNIT	COURSE CONTENT (45 Hours)	HR.							
	Introduction to Pharmacovigilance								
	History and development of Pharmacovigilance								
	Importance of safety monitoring of Medicine								
	WHO international drug monitoring programme								
	Pharmacovigilance Program of India(PvPI)								
	Introduction to adverse drug reactions								
	Definitions and classification of ADRs								
I	Detection and reporting	10							
	Methods in Causality assessment								
	Severity and seriousness assessment								
	Predictability and preventability assessment								
	Management of adverse drug reactions								
	Basic terminologies used in pharmacovigilance								
	Terminologies of adverse medication related events								
	Regulatory terminologies								
	Drug and disease classification								
	Anatomical, therapeutic and chemical classification of drugs								
	International classification of diseases								
	Daily defined doses								
	International Nonproprietary Names for drugs								
	Drug dictionaries and coding in pharmacovigilance								
	WHO adverse reaction terminologies								
	MedDRA and Standardized MedDRA queries								
II	WHO drug dictionary	10							
111	Eudravigilance medicinal product dictionary	10							
	Information resources in pharmacovigilance								
	Basic drug information resources								
	Specialized resources for ADRs								
	Establishing pharmacovigilance programme								
	Establishing in a hospital								
	Establishment & operation of drug safety department in industry								
	Contract Research Organizations (CROs)								
	Establishing a national programme								
	Vaccine safety surveillance								
III	Vaccine Pharmacovigilance	10							
1111	Vaccination failure	10							
	Adverse events following immunization								



Pharmacovigilance methods Passive surveillance – Spontaneous reports and case series Stimulated reporting Active surveillance – Sentinel sites, drug event monitoring and registries Comparative observational studies – Cross sectional study, case control study and cohort study and cohort study Targeted clinical investigations Communication in pharmacovigilance Effective communication in Pharmacovigilance Communication in Drug Safety Crisis management Communicating with Regulatory Agencies, Business Partners, Healthcare facilities & Media Safety data generation Pre-clinical phase Clinical phase Clinical phase Clinical phase Post approval phase (PMS) ICH Guidelines for Pharmacovigilance Organization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global pharmacovigilance requirements		Tradition Sity								
Stimulated reporting Active surveillance – Sentinel sites, drug event monitoring and registries Comparative observational studies – Cross sectional study, case control study and cohort study Targeted clinical investigations Communication in pharmacovigilance Effective communication in Pharmacovigilance Communication in Drug Safety Crisis management Communicating with Regulatory Agencies, Business Partners, Healthcare facilities & Media Safety data generation Pre-clinical phase Clinical phase Clinical phase Clinical phase Clinical phase Corganization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		Pharmacovigilance methods								
Active surveillance – Sentinel sites, drug event monitoring and registries Comparative observational studies – Cross sectional study, case control study and cohort study Targeted clinical investigations Communication in pharmacovigilance Effective communication in Pharmacovigilance Communication in Drug Safety Crisis management Communicating with Regulatory Agencies, Business Partners, Healthcare facilities & Media Safety data generation Pre-clinical phase Clinical phase Clinical phase Clinical phase Post approval phase (PMS) ICH Guidelines for Pharmacovigilance Organization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS		Passive surveillance – Spontaneous reports and case series								
Comparative observational studies – Cross sectional study, case control study and cohort study Targeted clinical investigations Communication in pharmacovigilance Effective communication in Pharmacovigilance Communication in Drug Safety Crisis management Communication with Regulatory Agencies, Business Partners, Healthcare facilities & Media Safety data generation Pre-clinical phase Clinical phase Clinical phase Post approval phase (PMS) ICH Guidelines for Pharmacovigilance Organization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		Stimulated reporting								
and cohort study Targeted clinical investigations Communication in pharmacovigilance Effective communication in Pharmacovigilance Communication in Drug Safety Crisis management Communicating with Regulatory Agencies, Business Partners, Healthcare facilities & Media Safety data generation Pre-clinical phase Clinical phase Post approval phase (PMS) ICH Guidelines for Pharmacovigilance Organization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		• Active surveillance – Sentinel sites, drug event monitoring and registries								
• Targeted clinical investigations Communication in pharmacovigilance • Effective communication in Pharmacovigilance • Communication in Drug Safety Crisis management • Communicating with Regulatory Agencies, Business Partners, Healthcare facilities & Media Safety data generation • Pre-clinical phase • Clinical phase • Clinical phase • Post approval phase (PMS) ICH Guidelines for Pharmacovigilance • Organization and objectives of ICH • Expedited reporting • Individual case safety reports • Periodic safety update reports • Post approval expedited reporting • Pharmacovigilance planning • Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions • Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population • Paediatrics & Geriatrics • Pregnancy and lactation CIOMS • CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance • D&C Act and Schedule Y, Differences in Indian and global		• Comparative observational studies – Cross sectional study, case control study								
Communication in pharmacovigilance • Effective communication in Pharmacovigilance • Communication in Drug Safety Crisis management • Communicating with Regulatory Agencies, Business Partners, Healthcare facilities & Media Safety data generation • Pre-clinical phase • Clinical phase • Clinical phase • Post approval phase (PMS) ICH Guidelines for Pharmacovigilance • Organization and objectives of ICH • Expedited reporting • Individual case safety reports • Periodic safety update reports • Post approval expedited reporting • Pharmacovigilance planning • Pharmacovigilance planning • Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions • Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population • Paediatrics & Geriatrics • Pregnancy and lactation CIOMS • CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance • D&C Act and Schedule Y, Differences in Indian and global		and cohort study								
Effective communication in Pharmacovigilance Communication in Drug Safety Crisis management Communicating with Regulatory Agencies, Business Partners, Healthcare facilities & Media Safety data generation		Targeted clinical investigations								
Communication in Drug Safety Crisis management Communicating with Regulatory Agencies, Business Partners, Healthcare facilities & Media Safety data generation Pre-clinical phase Clinical phase Post approval phase (PMS) ICH Guidelines for Pharmacovigilance Organization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		Communication in pharmacovigilance								
Communicating with Regulatory Agencies, Business Partners, Healthcare facilities & Media Safety data generation Pre-clinical phase Clinical phase Post approval phase (PMS) ICH Guidelines for Pharmacovigilance Organization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS COSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		Effective communication in Pharmacovigilance								
facilities & Media Safety data generation Pre-clinical phase Clinical phase Post approval phase (PMS) ICH Guidelines for Pharmacovigilance Organization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Ogod clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		Communication in Drug Safety Crisis management								
Safety data generation Pre-clinical phase Clinical phase Post approval phase (PMS) ICH Guidelines for Pharmacovigilance Organization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		• Communicating with Regulatory Agencies, Business Partners, Healthcare								
Pre-clinical phase Clinical phase Post approval phase (PMS) ICH Guidelines for Pharmacovigilance Organization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		facilities & Media								
Clinical phase Post approval phase (PMS) ICH Guidelines for Pharmacovigilance Organization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Organization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Pharmacovigilance planning Organization of adverse drug reactions Genetics related ADR with example focusing PK parameters. Prug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		Safety data generation								
Post approval phase (PMS) ICH Guidelines for Pharmacovigilance Organization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Odo clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS Orlinial and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		Pre-clinical phase								
IV Organization and objectives of ICH Organization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		Clinical phase								
Organization and objectives of ICH Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		• Post approval phase (PMS)								
Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		ICH Guidelines for Pharmacovigilance								
Expedited reporting Individual case safety reports Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global	137	Organization and objectives of ICH	00							
Periodic safety update reports Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global	1 1 1	Expedited reporting	08							
Post approval expedited reporting Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		Individual case safety reports								
Pharmacovigilance planning Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		Periodic safety update reports								
Good clinical practice in pharmacovigilance studies Pharmacogenomics of adverse drug reactions Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		Post approval expedited reporting								
Pharmacogenomics of adverse drug reactions • Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population • Paediatrics & Geriatrics • Pregnancy and lactation CIOMS • CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance • D&C Act and Schedule Y, Differences in Indian and global		Pharmacovigilance planning								
• Genetics related ADR with example focusing PK parameters. Drug safety evaluation in special population • Paediatrics & Geriatrics • Pregnancy and lactation CIOMS • CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance • D&C Act and Schedule Y, Differences in Indian and global		Good clinical practice in pharmacovigilance studies								
Drug safety evaluation in special population • Paediatrics & Geriatrics • Pregnancy and lactation CIOMS • CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance • D&C Act and Schedule Y, Differences in Indian and global		Pharmacogenomics of adverse drug reactions								
Paediatrics & Geriatrics Pregnancy and lactation CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global		Genetics related ADR with example focusing PK parameters.								
• Pregnancy and lactation CIOMS • CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance • D&C Act and Schedule Y, Differences in Indian and global		Drug safety evaluation in special population								
CIOMS • CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance • D&C Act and Schedule Y, Differences in Indian and global		Paediatrics & Geriatrics								
 CIOMS CIOMS Working Groups, CIOMS Form CDSCO (India) and Pharmacovigilance D&C Act and Schedule Y, Differences in Indian and global 	1 7	Pregnancy and lactation	07							
CDSCO (India) and PharmacovigilanceD&C Act and Schedule Y, Differences in Indian and global	•	CIOMS	07							
• D&C Act and Schedule Y, Differences in Indian and global		CIOMS Working Groups, CIOMS Form								
		CDSCO (India) and Pharmacovigilance								
pharmacovigilance requirements		• D&C Act and Schedule Y, Differences in Indian and global								
		pharmacovigilance requirements								



Recommended Books (Latest edition):

- a. Textbook of Pharmacovigilance: S K Gupta, Jaypee Brothers, Medical Publishers.
- b. Practical Drug Safety from A to Z by Barton Cobert, Pierre Biron, Jones and Bartlett Publishers.
- c. Mann's Pharmacovigilance: Elizabeth B. Andrews, Nicholas, Wiley Publishers.
- d. Stephens' Detection of New Adverse Drug Reactions: John Talbot, Patrick Walle, Wiley Publishers.
- e. An Introduction to Pharmacovigilance: Patrick Waller, Wiley Publishers.
- f. Cobert's Manual of Drug Safety and Pharmacovigilance: Barton Cobert, Jones & Bartlett Publishers.
- g. Textbook of Pharmacoepidemiolog edited by Brian L. Strom, Stephen E Kimmel, Sean Hennessy, Wiley Publishers.
- h. A Textbook of Clinical Pharmacy Practice -Essential Concepts and Skills: G. Parthasarathi, Karin Nyfort Hansen, Milap C. Nahata
- i. National Formulary of India
- j. Text Book of Medicine by Yashpal Munjal
- k. Text book of Pharmacovigilance: concept and practice by GP Mohanta and PK Manna
- 1. http://www.whoumc.org/DynPage.aspx?id=105825&mn1=7347&mn2=7259&mn3=729
- m. http://www.ich.org/
- n. http://www.cioms.ch/
- o. http://cdsco.nic.in/
- p. http://www.who.int/vaccine_safety/en/
- q. http://www.ipc.gov.in/PvPI/pv_home.html



FACULTY OF: Pharmaceutical Sciences **DEPARTMENT OF**: Pharmacognosy

SEMESTER: VIII CODE: BP806ET

NAME: Quality Control and Standardization of Herbals - Theory

Teaching & Evaluation Scheme: -

		Tea	Teaching Scheme (Hours)				Evaluation Scheme										
Subject					Credits		Th	eory			Prac	ctical					
Code	Subject	Th	Tu	Pr	Total		Interi Exai		End Seme		Interi Exai		End Sem Exan		Total		
							Marks	Hrs	Marks	Hrs	Marks	Hrs	Marks	Hrs			
	Quality Control and						15	1									
BP806ET	Standardization	3	1		4	4	10		75	3					100		
	of Herbals- Theory						(CM)										

Scope: In this subject the student learns about the various methods and guidelines for evaluation and standardization of herbs and herbal drugs. The subject also provides an opportunity for the student to learn cGMP, GAP and GLP in traditional system of medicines.

Objectives: Upon completion of the subject student shall be able to;

- Know WHO guidelines for quality control of herbal drugs
- Know Quality assurance in herbal drug industry
- Know the regulatory approval process and their registration in Indian and international markets
- Appreciate EU and ICH guidelines for quality control of herbal drugs

UNIT	COURSE CONTENT (45 Hours)	HR.
	• Basic tests for drugs - Pharmaceutical substances, Medicinal plants materials	
	and dosage forms	10
1	• WHO guidelines for quality control of herbal drugs.	10
	• Evaluation of commercial crude drugs intended for use	
	• Quality assurance in herbal drug industry of cGMP, GAP, GMP and GLP in	
II	traditional system of medicine. WHO Guidelines on current good	10
11	manufacturing Practices (cGMP) for Herbal Medicines WHO Guidelines on	10
	GACP for Medicinal Plants.	
	• EU and ICH guidelines for quality control of herbal drugs.	
III	• Research Guidelines for Evaluating the Safety and Efficacy of Herbal	10
	Medicines.	



IV	• Stability testing of herbal medicines. Application of various chromatographic techniques in standardization of herbal products. Preparation of documents for new drug application and export registration GMP requirements and Drugs & Cosmetics Act provisions.	08
	Regulatory requirements for herbal medicines. WHO I I I I I I I I I I I I I I I I I I I	
	WHO guidelines on safety monitoring of herbal medicines in	
\mathbf{V}	pharmacovigilance systems	07
	Comparison of various Herbal Pharmacopoeias.	
	Role of chemical and biological markers in standardization of herbal products	

Recommended Books: (Latest Editions)

- a. Pharmacognosy by Trease and Evans
- b. Pharmacognosy by Kokate, Purohit and Gokhale
- c. Rangari, V.D., Text book of Pharmacognosy and Phytochemistry Vol. I, Carrier Pub., 2006.
- d. Agrawal, S.S., Herbal Drug Technology. Universities Press, 2002.
- e. EMEA. Guidelines on Quality of Herbal Medicinal Products/Traditional Medicinal Products,
- f. Mukherjee, P.W. Quality Control of Herbal Drugs: An Approach to Evaluation of Botanicals, Business Horizons Publishers, New Delhi, India, 2002.
- g. Shinde M.V., Dhalwal K., Potdar K., Mahadik K. Application of quality control principles to herbal drugs. International Journal of Phytomedicine 1(2009); p. 4-8.
- h. WHO. Quality Control Methods for Medicinal Plant Materials, World Health Organization, Geneva, 1998. WHO. Guidelines for the Appropriate Use of Herbal Medicines. WHO Regional Publications, Western Pacific Series No 3, WHO Regional office for the Western Pacific, Manila, 1998.
- i. WHO. The International Pharmacopeia, Vol. 2: Quality Specifications, 3rd edn. World Health Organization, Geneva, 1981.
- j. WHO. Quality Control Methods for Medicinal Plant Materials. World Health Organization, Geneva, 1999.
- k. WHO. WHO Global Atlas of Traditional, Complementary and Alternative Medicine. 2 vol. set. Vol. 1 contains text and Vol. 2, maps. World Health Organization, Geneva, 2005.
- 1. WHO. Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants. World Health Organization, Geneva, 2004.



FACULTY OF: Pharmaceutical Sciences

DEPARTMENT OF: Pharmaceutical Chemistry

SEMESTER: VIII CODE: BP807ET

NAME: Computer Aided Drug Design - Theory

Teaching & Evaluation Scheme: -

	Name of the Subject	Tea	Teaching Scheme (Hours)				Evaluation Scheme										
Subject		Th						Th	eory			Prac	ctical				
Code		111	Tu	Pr	Total	Credit	Interi Exai		End Seme Exam		Interi Exai		End Sem Exan		Total		
							Marks	Hrs	Marks	Hrs	Marks	Hrs	Marks	Hrs			
	Computer Aided						15	1									
BP807ET	Drug Design- Theory	3	1		4	4	10 (CM)		75	3					100		

Scope: This subject is designed to provide detailed knowledge of rational drug design process and various techniques used in rational drug design process.

Objectives: Upon completion of the course, the student shall be able to understand

- Design and discovery of lead molecules
- The role of drug design in drug discovery process
- The concept of QSAR and docking
- Various strategies to develop new drug like molecules.
- The design of new drug molecules using molecular modeling software

UNIT	COURSE CONTENT (45 Hours)	HR.
I	 Introduction to Drug Discovery and Development Stages of drug discovery and development Lead discovery and Analog Based Drug Design Rational approaches to lead discovery based on traditional medicine, Random screening, Non-random screening, serendipitous drug discovery, lead discovery based on drug metabolism, lead discovery based on clinical observation. Analog Based Drug Design: Bioisosterism, Classification, Bioisosteric Replacement. Any three case studies 	
II	• Quantitative Structure Activity Relationship (QSAR) SAR versus QSAR, History and development of QSAR, Types of physicochemical parameters, experimental and theoretical approaches for the determination of physicochemical parameters such as Partition coefficient,	10



	Hammet's substituent constant and Tafts steric constant. Hansch analysis, Free	
	Wilson analysis, 3D-QSAR approaches like COMFA and COMSIA.	Ì
	Molecular Modeling and virtual screening techniques	
	• Virtual Screening techniques: Drug likeness screening, Concept of	İ
III	pharmacophore mapping and pharmacophore based Screening,	10
	• Molecular docking: Rigid docking, flexible docking, manual docking,	Ì
	Docking based screening. De novo drug design.	j
	• Informatics & Methods in drug design Introduction to Bioinformatics,	
IV	chemo informatics. ADME databases, chemical, biochemical and	08
	pharmaceutical databases.	İ
	Molecular Modeling: Introduction to molecular mechanics and quantum	
\mathbf{V}	mechanics. Energy Minimization methods and Conformational Analysis,	07
	global conformational minima determination.	j

Recommended Books (Latest Editions)

- 1. Robert GCK, ed., "Drug Action at the Molecular Level" University Prak Press Baltimore.
- 2. Martin YC. "Quantitative Drug Design" Dekker, New York.
- 3. Delgado JN, Remers WA eds "Wilson & Gisvolds's Text Book of Organic Medicinal & Pharmaceutical Chemistry" Lippincott, New York.
- 4. Foye WO "Principles of Medicinal chemistry 'Lea & Febiger.
- 5. Koro lkovas A, Burckhalter JH. "Essentials of Medicinal Chemistry" Wiley Interscience.
- 6. Wolf ME, ed "The Basis of Medicinal Chemistry, Burger's Medicinal Chemistry" John Wiley &Sons, New York.
- 7. Patrick Graham, L., An Introduction to Medicinal Chemistry, Oxford University Press.
- 8. Smith HJ, Williams H, eds, "Introduction to the principles of Drug Design" Wright Boston.
- 9. Silverman R.B. "The organic Chemistry of Drug Design and Drug Action" Academic Press, New York.



FACULTY OF: Pharmaceutical Sciences **DEPARTMENT OF**: Pharmacology

SEMESTER: VIII CODE: BP808ET

NAME: Cell and Molecular Biology -Theory

Teaching & Evaluation Scheme: -

	Name of the Subject	Tea	Teaching Scheme (Hours)				Evaluation Scheme									
Subject					Pr Total			Th	eory			Prac	ctical			
Code		Th	Tu	Pr		Credits					End Sem Exan		Total			
							Marks	Hrs	Marks	Hrs	Marks	Hrs	Marks	Hrs		
	Cell and Molecular						15	1								
BP808ET	Biology- Theory	3	1		4	4	10 (CM)		75	3			1	1	100	

Scope:

- Cell biology is a branch of biology that studies cells their physiological properties, their structure, the organelles they contain, interactions with their environment, their life cycle, division, death and cell function.
- This is done both on a microscopic and molecular level.
- Cell biology research encompasses both the great diversity of single-celled organisms like bacteria and protozoa, as well as the many specialized cells in multi-cellular organisms such as humans, plants, and sponges.

Objectives: Upon completion of the subject student shall be able to;

- Summarize cell and molecular biology history.
- Summarize cellular functioning and composition.
- Describe the chemical foundations of cell biology.
- Summarize the DNA properties of cell biology.
- Describe protein structure and function.
- Describe cellular membrane structure and function.
- Describe basic molecular genetic mechanisms.
- Summarize the Cell Cycle



UNIT	COURSE CONTENT (45 Hours)	HR.
I	 a. Cell and Molecular Biology: Definitions theory and basics and Applications. b. Cell and Molecular Biology: History and Summation. c. Properties of cells and cell membrane. d. Prokaryotic versus Eukaryotic e. Cellular Reproduction 	10
	f. Chemical Foundations – an Introduction and Reactions (Types)	
	a. DNA and the Flow of Molecular Information	
	b. DNA Functioning	
II	c. DNA and RNA	10
	d. Types of RNA	
	e. Transcription and Translation	
ш	a. Proteins: Defined and Amino Acids	
	b. Protein Structure	10
1111	c. Regularities in Protein Pathways d. Cellular Processes	10
	e. Positive Control and significance of Protein Synthesis	
	a. Science of Genetics	
	b. Transgenic and Genomic Analysis	
IV	c. Cell Cycle analysis	08
	d. Mitosis and Meiosis	
	e. Cellular Activities and Checkpoints	
	a. Cell Signals: Introduction	
	b. Receptors for Cell Signals	
V	c. Signaling Pathways: Overview	07
	d. Misregulation of Signaling Pathways	
	e. Protein-Kinases: Functioning	



Recommended Books (latest edition):

- a. W.B. Hugo and A.D. Russel: Pharmaceutical Microbiology, Blackwell Scientific Publications, Oxford London.
- b. Prescott and Dunn., Industrial Microbiology, 4th edition, CBS Publishers & Distributors, Delhi.
- c. Pelczar, Chan Kreig, Microbiology, Tata McGraw Hill edn.
- d. Malcolm Harris, Balliere Tindall and Cox: Pharmaceutical Microbiology.
- e. Rose: Industrial Microbiology.
- f. Probisher, Hinsdill et al: Fundamentals of Microbiology, 9th ed. Japan
- g. Cooper and Gunn's: Tutorial Pharmacy, CBS Publisher and Distribution.
- h. Peppler: Microbial Technology.
- i. Edward: Fundamentals of Microbiology.
- j. N.K. Jain: Pharmaceutical Microbiology, Vallabh Prakashan, Delhi
- k. Bergeys manual of systematic bacteriology, Williams and Wilkins- A Waverly company
- 1. B.R. Glick and J.J. Pasternak: Molecular Biotechnology: Principles and Applications of Recombinant DNA: ASM Press Washington D.C.
- m. RA Goldshy et. al., Kuby Immunology.



FACULTY OF: Pharmaceutical Sciences **DEPARTMENT OF**: Pharmaceutics

SEMESTER: VIII CODE: BP809ET

NAME: Cosmetic Science -Theory

Teaching & Evaluation Scheme: -

Teaching Scheme (Hours)						Evaluation Scheme									
Subject	Name of the					Credits	lits Theory Practical				ctical				
Code	Subject	Th	Tu	Pr	Total			Internal End Semester Internal				End Sem	Total		
							Exar	Exam Exam			Exar	n	Exam		
							Marks	Hrs	Marks	Hrs	Marks	Hrs	Marks	Hrs	
	Cosmetic						15	1							
BP809ET	Science-	3	1		4	4	10		75	3					100
	Theory						(CM)								

Scope: This course is designed to impart knowledge and skills necessary for the fundamental need for cosmetic and cosmeceutical products.

Objectives: Upon completion of the course, the students shall be able to understand

- Key ingredients used in cosmetics and cosmeceuticals.
- Key building blocks for various formulations.
- Current technologies in the market
- Various key ingredients and basic science to develop cosmetics and cosmeceuticals
- Scientific knowledge to develop cosmetics and cosmeceuticals with desired Safety, stability, and efficacy.

UNIT	COURSE CONTENT (45 Hours)	HR.
I	 Classification of cosmetic and cosmeceutical products, Definition of cosmetics as per Indian and EU regulations, Evolution of cosmeceuticals from cosmetics, cosmetics as quasi and OTC drugs Cosmetic excipients: Surfactants, rheology modifiers, humectants, emollients, preservatives. Classification and application Skin: Basic structure and function of skin. Hair: Basic structure of hair. Hair growth cycle. Oral Cavity: Common problem associated with teeth and gums. 	10
II	• Principles of formulation and building blocks of skin care products: Face wash, Moisturizing cream, Cold Cream, Vanishing cream and their advantages and disadvantages. Application of these products in formulation of cosmeceuticals.	10



	Antiperspirants & deodorants- Actives & mechanism of action.									
	• Principles of formulation and building blocks of Hair care products:									
	Conditioning shampoo, Hair conditioner, anti-dandruff shampoo. Hair oils.									
	Chemistry and formulation of Para-phylene diamine based hair dye.									
	• Principles of formulation and building blocks of oral care products: Toothpaste									
	for bleeding gums, sensitive teeth. Teeth whitening, Mouthwash.									
	Sun protection, Classification of Sunscreens and SPF.									
	• Role of herbs in cosmetics:									
	Skin Care: Aloe and turmeric									
III	Hair care: Henna and Amla.									
	Oral care: Neem and clove									
	• Analytical cosmetics: BIS specification and analytical methods for shampoo,									
	skincream and toothpaste.									
	• Principles of Cosmetic Evaluation: Principles of sebumeter, corneometer.									
IV	Measurement of TEWL, Skin Color, Hair tensile strength, Hair combing	08								
	properties Soaps, and syndet bars. Evolution and skin benefits.									
	• Oily and dry skin causes leading to dry skin, skin moisturisation. Basic									
	understanding of the terms comedogenic, dermatitis.									
T 7	Cosmetic problems associated with Hair and scalp: Dandruff, Hair fall causes	07								
V	Cosmetic problems associated with skin: blemishes, wrinkles, acne, prickly									
	heat and body odor.									
	Antiperspirants and Deodorants- Actives and mechanism of action									

Recommended Books (latest edition):

- 1. Harry's Cosmeticology, Wilkinson, Moore, Seventh Edition, George Godwin.
- 2. Cosmetics Formulations, Manufacturing and Quality Control, P.P. Sharma, 4thEdition, Vandana Publications Pvt. Ltd., Delhi.
- 3. Text book of cosmelicology by Sanju Nanda & Roop K. Khar, Tata Publishers.



FACULTY OF: Pharmaceutical Sciences **DEPARTMENT OF:** Pharmacology

SEMESTER: VIII CODE: BP810ET

NAME: Experimental Pharmacology -Theory

Teaching & Evaluation Scheme: -

	Name of the Subject	Teaching Scheme (Hours)					Evaluation Scheme								
Subject				Pr		Credits	Theory				Practical				
Code		Th	Tu		Total		Internal Exam		End Semester Exam		Internal Exam		End Semester Exam		Total
							Marks	Hrs	Marks	Hrs	Marks	Hrs	Marks	Hrs	
	Experimental						15	1							
BP810ET	Pharmacology-	3	1		4	4	10		75	3					100
	Theory						(CM)								

Scope: This subject is designed to impart the basic knowledge of preclinical studies in experimental animals including design, conduct and interpretations of results.

Objectives Upon completion of the course the student shall be able to,

- Appreciate the applications of various commonly used laboratory animals.
- Appreciate and demonstrate the various screening methods used in preclinical research
- Appreciate and demonstrate the importance of biostatistics and research methodology
- Design and execute a research hypothesis independently

UNIT	COURSE CONTENT (45 Hours)	HR.
I	 Laboratory Animals: Study of CPCSEA and OECD guidelines for maintenance, breeding and conduct of experiments on laboratory animals, Common lab animals: Description and applications of different species and strains of animals. Popular transgenic and mutant animals. Techniques for collection of blood and common routes of drug administration in laboratory animals, Techniques of blood collection and euthanasia. 	08
II	 Preclinical screening models a. Introduction: Dose selection, calculation and conversions, preparation of drug solution/suspensions, grouping of animals and importance of sham negative and positive control groups. Rationale for selection of animal species and sex for the study. b. Study of screening animal models for Diuretics, nootropics, anti-Parkinson's, anti-asthmatics 	10



	• Preclinical screening models: for CNS activity- analgesic, antipyretic, anti-	
	inflammatory, general anaesthetics, sedative and hypnotics, antipsychotic,	
	antidepressant, antiepileptic, anti-parkinsonism, Alzheimer's disease	
	• Preclinical screening models: for ANS activity, sympathomimetic,	
III	sympatholytic, parasympathomimetics, parasympatholytics, skeletal muscle	10
	relaxants, drugs acting on eye, local anesthetics.	
	• Preclinical screening models: for CVS activity- antihypertensive, diuretics,	
IV	antiarrhythmic, antidyslepidemic, anti aggregatory, coagulants, and	08
1 1	anticoagulants Preclinical screening models for other important drugs like	VO
	antiulcer, antidiabetic, anticancer and antiasthmatics.	
	• Research methodology and Bio-statistics Selection of research topic, review	
\mathbf{v}	of literature, research hypothesis and study design Pre-clinical data analysis	07
V	and interpretation using Students 't' test and One-way ANOVA. Graphical	U/
	representation of data	

Recommended Books (latest edition):

- 1. Fundamentals of experimental Pharmacology-by M.N. Ghosh
- 2. Hand book of Experimental Pharmacology-S.K. Kulakarni
- 3. CPCSEA guidelines for laboratory animal facility.
- 4. Drug discovery and Evaluation by Vogel H.G.
- 5. Drug Screening Methods by Suresh Kumar Gupta and S. K. Gupta
- 6. Introduction to biostatistics and research methods by PSS Sundar Rao and JRichard



FACULTY OF: Pharmaceutical Sciences

DEPARTMENT OF: Pharmaceutical Chemistry

SEMESTER: VIII CODE: BP811ET

NAME: Advanced Instrumentation Techniques - Theory

Teaching & Evaluation Scheme: -

Subject Code	Name of the Subject	Teaching Scheme (Hours)					Evaluation Scheme								
				Pr	Total	Credits		Th	eory		Practical				
		Th	Tu				Internal Exam		End Semester Exam		Internal Exam		End Semester Exam		Total
							Marks	Hrs	Marks	Hrs	Marks	Hrs	Marks	Hrs	
	Advanced						15	1							
BP811ET	Instrumentation Techniques- Theory	3	1		4	4	10 (CM)		75	3					100

Scope: This subject deals with the application of instrumental methods in qualitative and quantitative analysis of drugs. This subject is designed to impart advanced knowledge on the principles and instrumentation of spectroscopic and chromatographic hyphenated techniques. This also emphasizes on theoretical and practical knowledge on modern analytical instruments that are used for drug testing.

Objectives: Upon completion of the course the student shall be able to

- Understand the advanced instruments used and its applications in drug analysis
- Understand the chromatographic separation and analysis of drugs.
- Understand the calibration of various analytical instruments
- Know analysis of drugs using various analytical instruments.

UNIT	COURSE CONTENT (45 Hours)	HR.
I	 Nuclear Magnetic Resonance spectroscopy Principles of H-NMR and C-NMR, chemical shift, factors affecting chemical shift, coupling constant, Spin - spin coupling, relaxation, instrumentation and applications Mass Spectrometry- Principles, Fragmentation, Ionization techniques – Electron impact, chemical ionization, MALDI, FAB, Analyzers-Time off light and Quadrupole, instrumentation, applications 	08
II	• Thermal Methods of Analysis: Principles, instrumentation and applications of Thermogravimetric Analysis (TGA), Differential Thermal Analysis (DTA), Differential Scanning Calorimetry (DSC)	10



	• X-Ray Diffraction Methods: Origin of X-rays, basic aspects of crystals, X-ray								
	Crystallography, rotating crystal technique, single crystal diffraction, powder								
	diffraction, structural elucidation and applications.								
	• Calibration and validation-as per ICH and USFDA guidelines								
Ш	Calibration of following Instruments								
111	Electronic balance, UV-Visible spectrophotometer, IR spectrophotometer	10							
	Fluorimeter, Flame Photometer, HPLC and GC								
	• Radio Immuno Assay: Importance, various components, Principle, different								
IV	methods, Limitation and Applications of Radio Immuno Assay	08							
1 1	• Extraction techniques: General principle and procedure involved in the solid								
	phase extraction and liquid-liquid extraction								
V	• Hyphenated techniques-LC-MS/MS, GC-MS/MS, HPTLC-MS.	07							

Recommended Books (Latest Editions)

- 1. Instrumental Methods of Chemical Analysis by B.K Sharma
- 2. Organic spectroscopy by Y.R Sharma
- 3. Text book of Pharmaceutical Analysis by Kenneth A. Connors
- 4. Vogel's Text book of Quantitative Chemical Analysis by A.I. Vogel
- 5. Practical Pharmaceutical Chemistry by A.H. Beckett and J.B. Stenlake
- 6. Organic Chemistry by I. L. Finar
- 7. Organic spectroscopy by William Kemp
- 8. Quantitative Analysis of Drugs by D. C. Garrett
- 9. Quantitative Analysis of Drugs in Pharmaceutical Formulations by P. D. Sethi
- 10. Spectrophotometric identification of Organic Compounds by Silverstein



FACULTY OF: Pharmaceutical Sciences **DEPARTMENT OF**: Pharmacognosy

SEMESTER: VIII CODE: BP812ET

NAME: Dietary Supplements and Nutraceuticals -Theory

Teaching & Evaluation Scheme: -

Subject Code		Teaching Scheme (Hours)					Evaluation Scheme									
	Name of the					Credits	Theory					Prac	ctical			
	Subject	Th	Tu	Pr	Total		Internal Exam		End Semester Exam		Internal Exam		End Semester Exam		Total	
							Marks	Hrs	Marks	Hrs	Marks	Hrs	Marks	Hrs		
	Dietary				4	4	15	1		3						
	Supplements															
BP812ET	and	3	1				10		75						100	
	Nutraceuticals-						(CM)									
	Theory															

Scope: This subject covers foundational topic that are important for understanding the need and Requirements of dietary supplements among different groups in the population.

Objective: This module aims to provide an understanding of the concepts behind the theoretical applications of dietary supplements. By the end of the course, students should be able to:

- Understand the need of supplements by the different group of people to maintain healthy life.
- Understand the outcome of deficiencies in dietary supplements.
- Appreciate the components in dietary supplements and the application.
- Appreciate the regulatory and commercial aspects of dietary supplements including health claims.

UNIT	COURSE CONTENT (45 Hours)	HR.
	a) Definitions of Functional foods, Nutraceuticals and Dietary supplements.	
	Classification of Nutraceuticals, Health problems and diseases that can be	
	prevented or cured by Nutraceuticals i.e. weight control, diabetes, cancer,	
	heart disease, stress, osteoarthritis, hypertension etc.	
I	b) Public health nutrition, maternal and child nutrition, nutrition and ageing,	07
	nutrition education in community.	
	c) Source, Name of marker compounds and their chemical nature, Medicinal	
	uses and health benefits of following used as nutraceuticals/functional foods:	
	Spirulina, Soya bean, Ginseng, Garlic, Broccoli, Gingko, Flaxseeds	



	Phytochemicals as nutraceuticals: Occurrence and characteristic features											
	(chemical nature medicinal benefits) of following											
	a) Carotenoids- α and β-Carotene, Lycopene, Xanthophylls, leutin											
	b) Sulfides: Diallyl sulfides, Allyl trisulfide.											
	c) Polyphenolics: Reservetrol											
II	d) Flavonoids- Rutin, Naringin, Quercitin, Anthocyanidins, catechins, Flavones	15										
	e) Prebiotics / Probiotics.: Fructo oligosaccharides, Lacto bacillum											
	f) Phyto estrogens: Isoflavones, daidzein, Geebustin, lignans											
	g) Tocopherols											
	h) Proteins, vitamins, minerals, cereal, vegetables and beverages as functional											
	foods: oats, wheat bran, rice bran, sea foods, coffee, tea and the like.											
	a) Introduction to free radicals: Free radicals, reactive oxygen species,											
III	production of free radicals in cells, damaging reactions of free radicals on	07										
111	lipids, proteins, Carbohydrates, nucleic acids.	U/										
	b) Dietary fibers and complex carbohydrates as functional food ingredients.											
	a) Free radicals in Diabetes mellitus, Inflammation, Ischemic reperfusion											
	injury, Cancer, Atherosclerosis, Free radicals in brain metabolism and											
	pathology, kidney damage, muscle damage. Free radicals' involvement in											
	other disorders. Free radicals' theory of ageing.											
IV	b) Antioxidants: Endogenous antioxidants – enzymatic and no enzymatic	10										
	antioxidant defence, Superoxide dismutase, catalase, Glutathione peroxidase,											
	Glutathione Vitamin C, Vitamin E, α- Lipoic acid, melatonin Synthetic											
	c) antioxidants: Butylated hydroxy Toluene, Butylated hydroxy Anisole.											
	d) Functional foods for chronic disease prevention.											
	a) Effect of processing, storage and interactions of various environmental											
	factors on the potential of nutraceuticals.											
\mathbf{V}	b) Regulatory Aspects; FSSAI, FDA, FPO, MPO, AGMARK. HACCP and											
	GMPs on Food Safety. Adulteration of foods.											
	c) Pharmacopoeial Specifications for dietary supplements and nutraceuticals.											



References:

- a. Dietetics by Sri Lakshmi
- b. Role of dietary fibers and neutraceuticals in preventing diseases by K. T Agusti and P. Faizal: BS Publication.
- c. Advanced Nutritional Therapies by Cooper. K.A., (1996).
- d. The Food Pharmacy by Jean Carper, Simon & Schuster, UK Ltd., (1988).
- e. Prescription for Nutritional Healing by James F. Balch and Phyllis A. Balch 2nd Edn., Avery Publishing Group, NY (1997).
- f. G. Gibson and C. Williams Editors 2000 Functional foods Wood Head Publ. Co. London.
- g. Goldberg, I. Functional Foods. 1994. Chapman and Hall, New York.
- h. Labuza, T.P. 2000 Functional Foods and Dietary Supplements: Safety, Good Manufacturing Practice (GMPs) and Shelf Life Testing in *Essentials of Functional Foods* M.K. Sachmidl and T.P. Labuza eds. Aspen Press.
- i. Handbook of Nutraceuticals and Functional Foods, Third Edition (Modern Nutrition)
- j. Shils, ME, Olson, JA, Shike, M. 1994 *Modern Nutrition in Health and Disease*. Eighth edition. Lea and Fibiger



FACULTY OF: Pharmaceutical Sciences **DEPARTMENT OF:** Pharmaceutics

SEMESTER: VIII CODE: BP814ET

NAME: Pharmaceutical Product Development - Theory

Teaching & Evaluation Scheme: -

	Name of the Subject	Teaching Scheme (Hours)					Evaluation Scheme									
Subject		Th		Pr		Credits	Theory				Practical					
Code		111	Tu		Total		Internal		End Semester		Internal		End Semester		Total	
							Exar	n	Exan	1	Exai	n	Exan	n		
							Marks	Hrs	Marks	Hrs	Marks	Hrs	Marks	Hrs		
	Elective course on						15	1								
	Pharmaceutical															
BP814ET	Product	3	1		4	4	10		75	3					100	
	Development-						(CM)									
	Theory						, , ,									

Scope: Course designed to impart advanced knowledge and skills required to learn various aspects and concepts at pharmaceutical industries.

Objectives: Upon completion of the course, student shall be able to understand

- The elements of preformulation studies.
- The Active Pharmaceutical Ingredients and Generic Drug Product development
- Industrial Management and GMP Considerations.
- The optimization techniques

UNIT	COURSE CONTENT (45 Hours)	HR.
I	• Introduction to pharmaceutical product development, objectives, regulations related to preformulation, formulation development, stability assessment, manufacturing and quality control testing of different types of dosage forms	10
II	 An advanced study of Pharmaceutical Excipients in pharmaceutical product development with a special reference to the following categories Solvents and solubilizers Cyclodextrins and their applications Non - ionic surfactants and their applications Polyethylene glycols and sorbitol Suspending and emulsifying agents Semi solid excipients 	10



with specific industrial applications Optimization techniques in pharmaceutical product development. A study of various optimization techniques for pharmaceutical product development with specific examples. Optimization by factorial designs and their applications. A	Ш	 An advanced study of Pharmaceutical Excipients in pharmaceutical product development with a special reference to the following categories Tablet and capsule excipients Directly compressible vehicles Coat materials Excipients in parenteral and aerosols products Excipients for formulation of NDDS Selection and application of excipients in pharmaceutical formulations 	10
	IV	with specific industrial applications • Optimization techniques in pharmaceutical product development. A study of various optimization techniques for pharmaceutical product development with	08

Recommended Books (Latest editions)

- a. Pharmaceutical Statistics Practical and Clinical Applications by Stanford Bolton, Charles Bon; Marcel Dekker Inc.
- b. Encyclopedia of Pharmaceutical Technology, edited by James swar brick, Third Edition, Informa Healthcare publishers.
- c. Pharmaceutical Dosage Forms, Tablets, Volume II, edited by Herbert A. Lieberman and Leon Lachman; Marcel Dekker, Inc.
- d. The Theory and Practice of Industrial Pharmacy, Fourth Edition, edited by Roop k Khar, S P Vyas, Farhan J Ahmad, Gaurav K Jain; CBS Publishers and Distributors Pvt.Ltd. 2013.
- e. Martin's Physical Pharmacy and Pharmaceutical Sciences, Fifth Edition, edited by Patrick J. Sinko, BI Publications Pvt. Ltd.
- f. Targeted and Controlled Drug Delivery, Novel Carrier Systems by S. P. Vyas and R. K. Khar, CBS Publishers and Distributors Pvt. Ltd, First Edition 2012.
- g. Pharmaceutical Dosage Forms and Drug Delivery Systems, Loyd V. Allen Jr., Nicholas B. Popovich, Howard C. Ansel, 9th Ed. 40
- h. Aulton's Pharmaceutics The Design and Manufacture of Medicines, Michael E. Aulton,3rd Ed.
- i. Remington The Science and Practice of Pharmacy, 20th Ed.
- j. Pharmaceutical Dosage Forms Tablets Vol 1 to 3, A. Liberman, Leon Lachman and Joseph B. Schwartz



- k. Pharmaceutical Dosage Forms Disperse Systems Vol 1 to 3, H.A. Liberman, Martin, M.R and Gilbert S. Banker.
- 1. Pharmaceutical Dosage Forms Parenteral Medication Vol 1 & 2, Kenneth E. Avis and H. A. Libermann.
- m. Advanced Review Articles related to the topics.